Lumosa Therapeutics Co., Ltd.

Taipei Exchange 6535.TWO

Lumosa Therapeutics Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD -128.50 K

Lumosa Therapeutics Co., Ltd. Net Cash Used Provided By Financing Activities is USD -128.50 K for the year ending December 31, 2023, a -108.53% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Lumosa Therapeutics Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 1.51 M, a -90.32% change year over year.
  • Lumosa Therapeutics Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 15.56 M, a -48.67% change year over year.
  • Lumosa Therapeutics Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 30.31 M, a 12,267.99% change year over year.
  • Lumosa Therapeutics Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 245.08 K.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
Taipei Exchange: 6535.TWO

Lumosa Therapeutics Co., Ltd.

CEO Li Fang Pan
IPO Date July 16, 2015
Location
Headquarters No. 3-2, Park Street
Employees 47
Sector Health Care
Industries
Pharmaceuticals Biotechnology Clinical Trials
Description

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email